Results 51 to 60 of about 54,594 (319)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

Hemato, 2021
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in ...
Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk   +3 more
doaj   +1 more source

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC).
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, P. Zhou, Zhi-tang Dai, Kongming Wu   +8 more
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody

Antibodies, 2020
Amplification and overexpression of HER2 (human epidermal growth factor receptor 2), an ErbB2 receptor tyrosine kinase, have been implicated in human cancer and metastasis.
Jackie Cheng, Meina Liang, Miguel F. Carvalho, Natalie Tigue, Raffaella Faggioni, Lorin K. Roskos, Inna Vainshtein   +6 more
doaj   +1 more source

Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review

Pharmaceuticals, 2023
Bispecific antibodies have emerged as a promising class of therapeutics in the field of oncology, offering an innovative approach to target cancer cells while sparing healthy tissues. These antibodies are designed to bind two different antigens, enabling
Atulya Aman Khosla, Karan Jatwani, Rohit Singh, Aswanth Reddy, Ishmael Jaiyesimi, Aakash Desai   +5 more
doaj   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs

Pharmaceutics
Background/Objectives: All current FDA-approved antibody–drug conjugates (ADCs) are single-target and single-payload molecules that have limited efficacy in patients due to drug resistance.
Nicole A. Wilski, Peter Haytko, Zhengxia Zha, Simin Wu, Ying Jin, Peng Chen, Chao Han, Mark L. Chiu   +7 more
doaj   +1 more source

Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats

mAbs, 2023
Bispecific antibodies (bsAbs) enable dual binding of different antigens with potential synergistic targeting effects and innovative therapeutic possibilities.
Andreas V. Madsen, Peter Kristensen, Alexander K. Buell, Steffen Goletz   +3 more
doaj   +1 more source

A pivotal decade for bispecific antibodies?

mAbs
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs).
M. Surowka, C. Klein
semanticscholar   +1 more source